Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Non-Current Assets (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Non-Current Assets for 7 consecutive years, with $81.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 62.78% to $81.3 million in Q4 2025 year-over-year; TTM through Nov 2025 was $290.8 million, a 26.4% increase, with the full-year FY2025 number at $81.3 million, up 62.78% from a year prior.
  • Non-Current Assets was $81.3 million for Q4 2025 at Nurix Therapeutics, down from $81.9 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $165.7 million in Q4 2021 to a low of $40.2 million in Q3 2023.
  • A 5-year average of $85.9 million and a median of $81.6 million in 2023 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: soared 181.74% in 2021, then plummeted 61.47% in 2023.
  • Nurix Therapeutics' Non-Current Assets stood at $165.7 million in 2021, then plummeted by 40.65% to $98.3 million in 2022, then crashed by 38.87% to $60.1 million in 2023, then dropped by 16.87% to $50.0 million in 2024, then skyrocketed by 62.78% to $81.3 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Non-Current Assets are $81.3 million (Q4 2025), $81.9 million (Q3 2025), and $76.2 million (Q2 2025).